Gilead Sciences (GILD) Change in Accured Expenses (2009 - 2026)

Gilead Sciences has reported Change in Accured Expenses for 18 years, with the latest figure at -$702.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 187.7% year-over-year to -$702.0 million; the trailing twelve-month figure through Mar 2026 stood at -$452.0 million (down 1258.97% YoY), and the FY2025 full-year result was $6.0 million, down 94.44% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$702.0 million, down from -$395.0 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $811.0 million in Q3 2025, with the low at -$1.7 billion in Q1 2022.
• Historically, Change in Accured Expenses has averaged -$53.2 million across 5 years, with a median of $50.0 million in 2023.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 1348.0% — and 2025, when it sank 229.51%.
• Gilead Sciences' Change in Accured Expenses stood at $356.0 million in 2022, then decreased by 10.96% to $317.0 million in 2023, then slipped by 3.79% to $305.0 million in 2024, then slumped by 229.51% to -$395.0 million in 2025, then sank by 77.72% to -$702.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$702.0 million (Q1 2026), -$395.0 million (Q4 2025), and $811.0 million (Q3 2025), per Business Quant data.